Kaiser under a microscope

When it comes to healthcare, is Kaiser Permanente the wave of the future? The all-in-one hospital system epitomizes well-coordinated patient care and is ahead of the curve in embracing cutting-edge health IT, but can the system ultimately lower costs? The New York Times asks these questions and digs into some concerns expressed about the integrated system--its ability to be replicated, patient frustration at being locked in the system and unable to go to their choice doctor or hospital, and reported criticisms of long wait times. To learn more about pros and cons of the Kaiser Permanente healthcare model, check out the article:

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.